A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs
Categories (click each to see list of all clinical trials associated with that category): Thoracic (ONC)
Current Status: Open
Phase: I (Cancer Control)
Principal Investigator: Sharma, Bhavina
Contact Information:
Michaela Savine
misavine@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06228326?term=NCT06228326&rank=1#participation-criteria
Summary
Primary:
To evaluate safety and tolerability of inhaled KB707 monotherapy and in combination with Keytruda, with or without chemotherapy
Secondary:
To evaluate whether the proposed dose ranges include the maximum tolerated dose (MTD) of KB707
To evaluate the preliminary efficacy of inhaled KB707 monotherapy and in combination with Keytruda, with or without chemotherapy by RECIST v1.1,
Exploratory:
To assess the effect of KB707 monotherapy and in combination with Keytruda, with or without chemotherapy on circulating immune effectors
To evaluate preliminary efficacy of KB707 monotherapy and in combination with Keytruda, with or without chemotherapy by iRECIST.